- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 36
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia and Predominant Negative Symptoms
- Interventions
- SPD489 (lisdexamfetamine dimesylate), Placebo matching SPD489 (lisdexamfetamine dimesylate)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
- Conditions
- Major Depressive Disorder
- Interventions
- SPD489 (Lisdexamfetamine dimesylate ), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Carson, California • Irvine, California + 42 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SPD489
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 50
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 15
- States / cities
- Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
- Conditions
- Sleep Deprivation
- Interventions
- SPD489 20 mg, SPD489 50 mg, SPD489 70 mg, Armodafinil, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more